ToolGen shares surge as Britain gives world's first nod to gene-editing treatment
ToolGen share is trading at 61,800 won ($47.68) as of 11:05 a.m., up 29.83 percent from the previous trading day.
ToolGen holds a patent on so-called genetic scissors, a gene-editing tool.
Britain on Thursday became the first country in the world to give the nod to Casgevy, a Crispr gene-editing tool developed by Vertex Pharmaceuticals and Crispr Therapeutics, to treat hereditary blood disorders.
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)